Monitoring the pharmacokinetics of pyridinium aldoximes in the body

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 596-610

  Kalasz H ^a   Furesz J ^b   Tekes, K ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Institute of Health Protection Budapest   (Hungary)

Author keywords

K 203; K 27; K 48; Pralidoxime; Pyridinium aldoximes

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 1 (4 CARBAMOYLPYRIDINIO) 4 (2 HYDROXYIMINOMETHYLPYRIDINIO) 2 BUTENE DIBROMIDE; 1 [2,4 BIS(HYDROXYIMINOMETHYL)PYRIDINIO] 1' (4 CARBAMOYLPYRIDINIO)DIMETHYL ETHER DIIODIDE; ACETYLCHOLINESTERASE; ATROPINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CHOLINESTERASE REACTIVATOR; CYCLOSARIN; K 156; K 203; K 27; K 33; K 48; K 75; METHOXIME; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; OBIDOXIME; ORGANOPHOSPHATE; OXIME DERIVATIVE; PRALIDOXIME; PRALIDOXIME CHLORIDE; PRALIDOXIME MESILATE; PYRIDINIUM ALDOXIME DERIVATIVE; SARIN; SOMAN; TABUN; THIAMINE; TRIMEDOXIME; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIDOTE; OXIME; PYRIDINIUM DERIVATIVE;

AGRICULTURE; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME REACTIVATION; ENZYME REGULATION; FLUID THERAPY; HUMAN; INTOXICATION; LOADING DRUG DOSE; LOW DRUG DOSE; NONHUMAN; OXYGEN THERAPY; PATIENT MONITORING; RECOMMENDED DRUG DOSE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; METABOLISM; REVIEW;

ACETYLCHOLINESTERASE; ANIMALS; ANTIDOTES; BLOOD-BRAIN BARRIER; HUMANS; OXIMES; PYRIDINIUM COMPOUNDS;

EID: 67649892037     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788167565     Document Type: Article

References (205)

1. Petroianu, G.A. The history of cholinesterase inhibitors: who was Moschnin(e)? Pharmazie, 2008, 63, 325-7.
2. Dart, C.R. Ed.; Medical Toxicology, Lippincott Williams & Wilkins, Philadelphia, 3rd ed, 2004.
3. Klaassen, C.D. Ed.; Casarett and Doull's Toxicology. The Basic Science of Poisons, McGraw-Hill Medical, New York, 7th ed, 2008.
4. Brunton, L.L.; Lazo, J.S.; Parker, K.L. Eds; Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill Medical, New York, 9th ed, 2006.
5. Eyer, P. The role of oximes in the management of organophosphorous pesticide poisoning. Toxicol. Rev., 2003, 22, 165-90.
6. Suzuki, T.; Morita, H.; Ono, K.; Maekawa, K.; Nagai, R.; Yazaki, Y. Sarin poisoning in Tokyo subway. Lancet, 1995, 345, 980-1.
7. Nagao, M.; Takatori, T.; Matsuda, Y.; Nakayima, M; Iwase, H.; Iwadate, K. Definitive evidence for the acute sarin poisoning diagnosis in the Tokyo subway. Toxicol. Appl. Pharmacol., 1997, 144, 198-203.
8. Wilson, I.B.; Ginsburg, S. A powerful reactivator of alkylphosphate inhibited acetylcholinesterase. Biochim. Biophys. Acta, 1955, 28, 168-70.
9. www.google.com
10. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Sheen, R.; Nagelkerke, N. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs. pyridostigmine. Toxicol. Appl. Pharmacol., 2007, 219, 235-40.
11. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Shafiullah, M.; Sheen, R. Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different pointsin-time in rats. Mol. Cell Biochem., 2006, 285, 79-86.
12. Petroianu, G.A.; Hasan, M.Y.; Arafat, K.; Nurulain, S.M.; Schmitt, A. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of tiapride. J. Appl. Toxicol., 2005, 25, 562-7.
13. Petroianu, G.A.; Schmitt, A.; Arafat, K.; Hasan, M.Y. Weak inhibitors protect cholinesterases from stronger inhibitors (dichlorvos): in vitro effect of tiapride. Int. J. Toxicol., 2005, 24, 79-86.
14. Petroianu, G.A.; Arafat, K.; Schmitt, A.; Hasan, M.Y. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J. Appl. Toxicol., 2005, 25, 60-7.
15. Petroianu, G.; Kühn, F.; Arafat, K.; Zuleger, K.; Missler, A. In vitro protection of plasma cholinesterases by metoclopramide from inhibition by mipafox. J. Appl. Toxicol., 2004, 24, 143-6.
16. Petroianu, G.A.; Hasan, M.Y.; Kosanovic, M.; Vijayasarathy, C.; Saleh, A.M. Metoclopramide protection of cholinesterase from paraoxon inhibition. Vet. Hum. Toxicol., 2003, 45, 251-3.
17. Petrikovics, I.; Cheng, T.C.; Papahadjopoulos, D.; Hong, K.; Yin, R.; DeFrank, J.J.; Jaing, J.; Song, Z.H.; McGuinn, W.D.; Sylvester, D.; Pei, I.; Madec, J.; Tamulinas, C.; Jászberényi, J.C.; Barcza, T.; Way, J.L. Long circulating liposomes encapsulating organophosphorous acid anhydrolase in diisopropylfluorophosphate antagonism. Toxicol. Sci., 2000, 57, 16-21.
18. Becker, G. Kawan, A. Szinicz, L. Direct reaction of oximes with sarin, soman, or tabun in vitro. Arch. Toxicol., 1997, 71, 714-8.
19. Becker, G.; Kawan, A.; Gutzeit, D.; Worek, F.; Szinicz, L. Direct reaction of oximes with crotylsarin, cyclosarin, or VX in vitro. Arch. Toxicol., 2007, 81, 415-20.
20. Pohanka, M.; Jun, D.; Kuca, K. Photometric microplate assay for estimation of the efficacy of paraoxon-inhibited acetylcholinesterase reactivation. J. Enzyme Inhib. Med. Chem., 2008, 9, 1-4.
21. Kassa, J.; Karasova, J.; Bajgar, J.; Kuca, K.; Musilek, K. A comparison of the therapeutic and reactivating efficacy of newly developed bispyridinium compounds (K206, K269) with currently available oximes against tabun in rats and mice. J. Enzyme Inhib. Med. Chem., 2008, 23, 776-80.
22. Oh, K.A.; Park, N.J.; Park, N.S.; Kuca, K.; Jun, D.; Jung, Y.S. Reactivation of DFP- and paraoxon-inhibited acetylcholinesterases by pyridinium oximes. Chem. Biol. Interact., 2008, 175, 365-7.
23. Musilek, K.; Jampilek, J.; Dohnal, J.; Jun, D.; Gunn-Moore, F.; Dolezal, M.; Kuca, K. RP-HPLC determination of the lipophilicity of bispyridinium reactivators of acetylcholinesterase bearing a but-2-ene connecting linker. Anal. Bioanal. Chem., 2008, 391, 367-72.
24. Csermely, T.; Petroianu, G.; Kuca, K.; Fürész, J.; Gulyás, Z.; Laufer, R.; Kalász, H. TLC of quaternary pyridinium aldoximes, antidotes to organophosphorous esterase inhibitors. J. Planar Chromatogr., 2007, 20, 39-42.
25. Laufer, R.; Báthori, M.; Csermely, T.; Petroianu, G.; Kuca, K.; Tóth, N.; Kalász, H. TLC determination of hydrophilicity parameter of some pyridinium aldoximes. J. Liquid Chromatogr., 2007, 30, 2337-44.
26. The PrologP program is a Trademark of CompuDrug Inc., www.compudrug.com
27. Molnar, L.; Keseru, G.M.; Papp, A.; Gulyás, Zs.; Darvas, F. A neural network based prediction of octanol-water partition coefficients using atomic5 fragmental descriptors. Bioorg. Med. Chem. Lett., 2004, 14, 851-3.
28. Corvino, T.F.; Nahata, M.C.; Angelos, M.G.; Tschampel, M.M.; Morosco, R.S.; Zerkle, J.; Nelson, R.N. Availability, stability, and sterility of pralidoxime for mass casuality use. Ann. Emerg. Med., 2006, 47, 272-7.
29. Paddle, B.M.; Dowling, M.H. Simple high-performance liquid chromatographic method for assessing the deterioration of atropine-oxime mixtures employed as antidotes in the treatment of nerve agent poisoning. J. Chromatogr., 1993, 648, 373-80.
30. Bajgar, J.; Fusek, J.; Kuca, K.; Bartosova, L.; Jun, D. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev. Med. Chem., 2007, 7, 461-6.
31. Bajgar, J.; Hajek, P.; Slizova, D.; Krs, O.; Fusek, J.; Kuca, K.; Jun, D.; Bartosova, L.; Blaha, V. Changes of acetylcholinesterase activity in different rat brain areas following intoxication with nerve agents: biochemical and histochemical study. Chem. Biol. Interact., 2007, 165, 14-21.
32. Kuca, K.; Jun, D.; Musilek, K. Structural requirements of acetylcholinesterase reactivators. Mini Rev. Med. Chem., 2006, 6, 269-77.
33. Kuca, K.; Dohnal, V. 1,3-Bis(2-hydroxyiminomethylpyridinium) propane as the potential reactivator of the acetylcholinesterase inhibited by nerve agents. Acta Medica (Hradec Kralove), 2004, 47, 167-9.
34. Kuca, K.; Kassa, J. In vitro reactivation of acetylcholinesterase using the oxime K027. Vet. Hum. Toxicol., 2004, 46, 15-8.
35. Yamane, G.K. Accidental injection of a U.S. Air Force aviater by a pralidoxime autoinjector: a case report. Aviat. Space Environ. Med., 1999, 70, 1110-2.
36. Kiderlen, D.; Eyer, P.; Worek, F. Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolysed by human paraoxonase (PON1). Biochem Pharmacol., 2005, 69, 1853-67.
37. Worek, F.; Reiter, G.; Eyer, P.; Szinicz, L. Reactivation kinetics of acetylcholinesterae from different species inhibited by highly toxic organophosphates. Arch. Toxicol., 2002, 76, 523-9.
38. Worek, F.; Eyer, P.; Aurbek, N.; Szinicz, L.; Thiermann, H. Revent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxic. Appl. Pharmacol., 2007, 219, 226-34.
39. Wolthuis, O.; Vanwersch, R.A.; Van der Wiej, H.J. The efficacy of some bis-pyridinium oximes as antidotes to soman in isolated muscles of several species including man. Eur. J. Pharmacol., 1981, 70, 355-69.
40. Seeger, T.; Worek, F.; Szinicz, L.; Thiermann, H. Reevaluation of indirect field stimulation technique to demonstrate oxime effectiveness in OP-poisoning in muscles in vitro. Toxicology, 2007, 233, 209-13.
41. Worek, F.; Thiermann, H.; Szinicz, L.; Eyer, P. Kinetic analysis of interactions between human acetylcholinesterases, structurally different organophosphorous compounds and oximes. Biochem. Pharmacol., 2004, 68, 2237-48.
42. Thiermann, H.; Szinicz, L.; Eyer, P.; Felgenhauer, N.; Zilker, T.; Worek, F. Lessons to be learnt from organophosphorous pesticide poisoning for the treatment of nerve agent poisoning. Toxicology, 2007, 233, 145-54.
43. Thompson, D.F.; Thompson, G.D.; Greenwood, R.B.; Trammel, H.L. Therapeutic dosing of pralidoxime chloride. Drug Intell. Clin. Pharm., 1987, 21, 590-3,
44. Rumack, B.H. Organophosphate management. In: Poisindex, Englewood, CO: Micromedex, 1986.
45. Cassel, G.; Kalsson, L.; Waara, L.; Ang, K.W.; Göransson-Nyberg, A. Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: A microdialysis study. Eur. J. Pharmacol., 1997, 332, 43-52.
46. Krummer, H.; Thiermann, H.; Worek, F.; Eyer, P. Equipotent cholinesterase reactivation in vitro by the nerve agent antidotes HI-6 dichloride and HI-6 dimethanesulphonate. Arch. Toxicol., 2002, 76, 589-95.
47. Thiermann, H.; Seidl, S.; Eyer, P. HI-6 dimethylsulphonate has better dissolution properties than HI-6 dichloride for application in dry/wet autoinjectors. Int. J. Pharm., 1996, 137, 167-76.
48. Cabal, J.; Kuca, K.; Kassa, J. Specification of the structure of oximes able to reactivate tabun-inhibited acetylcholinesterase. Basic Clin. Pharmacol. Toxicol., 2004, 95, 81-6.
49. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Nagelkerke, N.; Kassa, J.; Kuca, K. New K-oximes (K-27 and K-48) in comparison with obidoxime (LuH-6), HI-6, trimedoxime (TMB-4), and pralidoxime (2-PAM): Survival in rats exposed IP to the organophosphate poisoning. Toxicol. Mech. Methods, 2007, 17, 401-8.
50. Kassa, J.; Karasova, J.; Musilek, K.; Kuca, K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology, 2008, 243, 311-6.
51. Musilek, K.; Jun, D.; Cabal, J.; Kassa, J.; Gunn-Moore, F.; Kuca, K. Design of a potent reactivator of tabun-inhibited acetylcholinesterase - synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4- (4-hydroxyiminomethylpyridinium)- but-2-ene dibromide (K203). J. Med. Chem., 2007, 50, 5514-8.
52. Petroianu, G.A.; Arafat, K.; Nurulain, S.M.; Kuca, K.; Kassa, J. In vitro oxime reactivation of red blood cell acetylcholinesterase inhibited by methyl-paraoxon. J. Appl. Toxicol., 2007, 27, 168-75.
53. Lorke, D.E.; Hasan, M.Y.; Arafat, K.; Kuca, K.; Musilek, K.; Schmitt, A.; Petroianu, G.A. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropylfluorophosphate. J. Appl. Toxicol., 2008, 28, 422-9.
54. Petroianu, G.A.; Arafat, K.; Kuca, K.; Kassa, J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibited by paraoxon. J. Appl. Toxicol., 2006, 26, 64-71.
55. Petroianu, G.; Arafat, K.; Kosanovic, M.; Saleh, A.; Camasamudram, V.; Hasan, M.Y. In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J. Appl. Toxicol., 2003, 23, 447-51.
56. Lorke, D.E.; Nurulain, S.M.; Hasan, M.Y.; Kuca, K.; Musilek, K.; Petroianu, G.A. Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropyl-fluorophosphate toxicity. J. Appl. Toxicol., 2008, 28, 920-8.
57. Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Shafiullah, M.; Nagelkerke, N.; Petroianu, G.A. Effect of intrathecal pralidoxime administration upon survival of rats exposed to the organophosphate paraoxon. Neurotoxicology, 2008, 29, 663-70.
58. Petroianu, G.A. Cholinesterase pseudo-activity, oximolysis, esterolysis, thiocholine ester hydrolysis by oximes: what's in a name? Toxicol. Lett., 2007, 168, 88-9.
59. Petroianu, G.A.; Nurulain, S.M.; Arafat, K.; Rajan, S.; Hasan, M.Y. Effect of pyridostigmine, pralidoxime and their combination on survival and cholinesterase activity in rats exposed to the organophosphate paraoxon. Arch. Toxicol., 2006, 80, 777-84.
60. Petroianu, G.A.; Nurulain, S.M.; Nagelkerke, N.; Al-Sultan, M.A.; Kuca, K.; Kassa, J. Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: survival in rats exposed to the organophosphate paraoxon. J. Appl. Toxicol., 2006, 26, 262-8.
61. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Sheen, R.; Saleh, A.; Schmitt, A. Protective drugs in acute large-dose exposure to organophosphates: a comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth. Analg., 2005, 100, 382-6.
62. Petroianu, G.A.; Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Sha Ullah, M.; Naseer, O.: Protective agents in acute high-dose organophosphate exposure: comparison of ranitidine with pralidoxime in rats. J. Appl. Toxicol., 2005, 25, 68-73.
63. Hasan, M.Y.; Nurulain, S.M.; Arafat, K.; Naseer, O.P.; Petroianu, G.A. In vivo metoclopramide protection of cholinesterase from paraoxon inhibition: direct comparison with pralidoxime in subchronic low-dose exposure. J. Appl. Toxicol., 2004, 24, 257-60.
64. Petroianu, G.A.; Kalász, H. Comparison of the ability of pyridinium aldoximes to reactivate human RBC cholinesterases inhibited by ethyl- and methyl paraoxon. Curr. Org. Chem., 2007, 11, 1624-1634.
65. Petroianu, G.A.; Lorke, D.E. Pyidinium oxime reactivators of cholinesterase inhibited by diisopropyl-fluorophosphate (FP): predictive value of in-vitro testing for in-vivo efficacy. Mini Rev. Med. Chem., in press, 2008.
66. Kassa, J.; Kuca, K.; Karasova, J.; K. The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev. Med. Chem., 2008, 8, 1134-43.
67. Kuca, K.; Bielavský, J.; Cabal, J.; Kassa, J. Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2003, 13, 3545-7.
68. Kuca, K.; Kassa, J. A comparison of the ability of a new bispyridinium oxime - 1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium) butane dibromide and currently used oximes to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. J. Enzyme Inhib. Med. Chem., 2003, 18, 529-35.
69. Kuca, K.; Kassa, J. Oximes-induced reactivation of rat brain acetylcholinesterase inhibited by VX agent. Hum. Exp. Toxicol., 2004, 23, 167-71.
70. Kuca, K.; Patocka, J. Reactivation of cyclosarin-inhibited rat brain acetylcholinesterase by pyridinium - oximes. J. Enzyme Inhib. Med. Chem., 2004, 19, 39-43.
71. Kuca, K, Sevelová-Bartosová, L, Krejcová-Kunesová, G. In vitro reactivation of acetylcholinesterase inhibited by cyclosarin using bisquaternary pyridinium aldoximes K005, K033, K027 AND K048. Acta Medica (Hradec Kralove), 2004, 47, 107-9.
72. Kuca, K.; Cabal, J.; Kassa, J. A comparison of the efficacy of a bispyridinium oxime - 1,4-bis-(2-hydroxyiminomethylpyridinium) butane dibromide and currently used oximes to reactivate sarin, tabun or cyclosarin-inhibited acetylcholinesterase by in vitro methods. Pharmazie, 2004, 59, 795-8.
73. Sevelová, L.; Kuca, K.; Krejcová-Kunesová, G. Antidotal treatment of GF-agent intoxication in mice with bispyridinium oximes. Toxicology, 2005, 207, 1-6.
74. Bartosová, L.; Kunesová, G.; Kuca, K.; Vachek, J. Therapeutic efficacy of different antidotal mixtures against poisoning with GF-agent in mice. Acta Medica (Hradec Kralove), 2004, 47, 249-51.
75. Kuca, K.; Cabal, J.; Kassa, J. A comparison of the potency of newly developed oximes (K005, K027, K033, K048) and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited rat brain acetylcholinesterase by in vitro methods. J. Toxicol. Environ. Health A., 2005, 68, 677-86.
76. Kim, T.H.; Kuca, K.; Jun, D.; Jung, Y.S. Design and synthesis of new bis-pyridinium oxime reactivators for acetylcholinesterase inhibited by organophosphorous nerve agents. Bioorg. Med. Chem. Lett., 2005, 15, 2914-7.
77. Kuca, K.; Cabal, J.; Kassa, J.; Jun, D.; Hrabinová, M. Comparison of in vitro potency of oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited acetylcholinesterase in various parts of pig brain. J. Appl. Toxicol., 2005, 25, 271-6.
78. Kuca, K.; Cabal, J.; Jun, D.; Kassa, J.; Bartosová, L.; Kunesová, G. In vitro reactivation potency of some acetylcholinesterase reactivators against sarin- and cyclosarin-induced inhibitions. J. Appl. Toxicol., 2005, 25, 296-300.
79. Kuca, K.; Cabal, J.; Musilek, K.; Jun, D.; Bajgar, J. Effective bisquaternary reactivators of tabun-inhibited AChE. J. Appl. Toxicol., 2005, 25, 491-5.
80. Kuca, K.; Cabal, J.; Kassa, J. In vitro reactivation of sarin-inhibited brain acetylcholinesterase from different species by various oximes. J. Enzyme Inhib. Med. Chem., 2005, 20, 227-32.
81. Picha, J.; Kuca, K.; Kivala, M.; Kohout, M.; Cabal, J.; Liska, F. A new group of monoquaternary reactivators of acetylcholinesterase inhibited by nerve agents. J. Enzyme Inhib. Med. Chem., 2005, 20, 233-7.
82. Cabal, J.; Kuca, K.; Jun, D.; Bajgar, J.; Hrabinová, M. [A comparison of the efficacy of the reactivators of acetylcholinesterase inhibited with tabun]. Ceska Slov. Farm., 2005, 54, 192-5.
83. Krejcova-Kunesova, G.; Bartosova, L.; Kuca, K. Signs of cyclosarin-induced neurotoxicity and its pharmacological treatment with quaternary pyridinium-oximes reactivators. Toxicology, 2005, 216, 32-40.
84. Kuca, K.; Bartosová, L.; Jun, D.; Patocka, J.; Cabal, J.; Kassa, J.; Kunesová, G. New quaternary pyridine aldoximes as casual antidotes against nerve agents intoxications. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czech Repub., 2005, 149, 75-82.
85. Kuca, K.; Cabal, J.; Kassa, J.; Jun, D.; Hrabinová, M. A comparison of the potency of the oxime HLö-7 and currently used oximes (HI-6, pralidoxime, obidoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. Acta Med. (Hradec Kralove), 2005, 48, 81-6.
86. Musilek, K.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2006, 16, 622-7.
87. Calić, M.; Vrdoljak, A.L.; Radić, B.; Jelić, D.; Jun, D.; Kuca, K.; Kovarik, Z. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicology, 2006, 219, 85-96.
88. Musilek, K.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of a novel series of bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. J. Enzyme Inhib. Med. Chem., 2005, 20, 409-15.
89. Bartosova, L.; Kuca, K.; Jun, D.; Kunesova, G. Bispyridinium oximes as antidotal treatment of cyclosarin poisoning-in vitro and in vivo testing. Int. J. Toxicol., 2005, 24, 399-402.
90. Kuca, K.; Bartosova, L.; Kassa, J.; Cabal, J.; Bajgar, J.; Kunesova, G.; Jun, D. Comparison of the potency of newly developed and currently available oximes to reactivate nerve agent-inhibited acetylcholinesterase in vitro and in vivo. Chem. Biol. Interact., 2005, 15, 367-8.
91. Kassa, J.; Kuca, K.; Cabal, J. A comparison of the potency of trimedoxime and other currently available oximes to reactivate tabun-inhibited acetylcholinesterase and eliminate acute toxic effects of tabun. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czech Repub., 2005, 149, 419-23.
92. Bartosová, L.; Kuca, K.; Kunesová, G. Effectivity of new acetylcholinesterase reactivators in treatment of cyclosarin poisoning in mice and rats. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czech Repub., 2005, 149, 425-7.
93. Kuca, K.; Cabal, J.; Jun, D.; Kassa, J.; Bartosová, L.; Kunesová, G.; Dohnal, V. Strategy for the development of new acetylcholinesterase reactivators - antidotes used for treatment of nerve agent poisonings. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czech Repub., 2005, 149, 429-31.
94. Kuca, K.; Jun, D.; Cabal, J.; Hrabinova, M.; Bartosova, L.; Opletalova, V. Russian VX: inhibition and reactivation of acetylcholinesterase compared with VX agent. Basic Clin. Pharmacol. Toxicol., 2006, 98, 389-94.
95. Kuca, K.; Cabal, J.; Kassa, J.; Jun, D.; Hrabinova, M. In vitro potency of H oximes (HI-6, HLö-7), the oxime BI-6, and currently used oximes (pralidoxime, obidoxime, trimedoxime) to reactivate nerve agent-inhibited rat brain acetylcholinesterase. J. Toxicol. Environ. Health A., 2006, 69, 1431-40.
96. 2 linkers between pyridinium rings and their reactivity against VX. Bioorg. Med. Chem. Lett., 2006, 16, 4852-5.
97. Musílek, K.; Kuca, K.; Jun, D.; Dohnal, V.; Kim, T.H.; Jung, Y.S.; Dolezal, M. [Synthesis of reactivators of phosphorylated acetylcholinesterase of bis-pyridiniumdialdoxime type with a 3-oxapentane connecting chain and their testing in vitro on a model of the enzyme inhibited by chlorpyrifos and methylchlorpyrifos]. Ceska Slov. Farm. 2006, 55, 115-9.
98. Bajgar, J.; Fusek, J.; Bartosova, L.; Jun, D.; Kuca, K. Evaluation of reactivation test in anaesthetized dogs with experimental intoxication with nerve agents. J. Appl. Toxicol., 2006, 26, 439-43.
99. Kuca, K.; Cabal, J.; Jun, D.; Hrabinova, M. In vitro evaluation of acetylcholinesterase reactivators as potential antidotes against tabun nerve agent poisonings. Drug Chem. Toxicol. 2006, 29, 443-9.
100. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of asymmetrical bispyridinium compounds bearing cyano-moiety and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2006, 16, 5673-6.
101. Kassa, J.; Jun, D.; Kuca, K. The reactivating and therapeutic efficacy of oximes to counteract Russian VX poisonings. Int. J. Toxicol., 2006, 25, 397-401.
102. Kassa, J.; Kuca, K.; Cabal, J.; Paar, M. A comparison of the efficacy of new asymmetric bispyridinium oximes (K027, K048) with currently available oximes against tabun by in vivo methods. J. Toxicol. Environ. Health A., 2006, 69, 1875-82.
103. Lucić Vrdoljak, A.; Calić, M.; Radić, B.; Berend, S.; Jun, D.; Kuca, K.; Kovarik, Z. Pretreatment with pyridinium oximes improves antidotal therapy against tabun poisoning. Toxicology, 2006, 228, 41-50.
104. Hrabinova, M.; Musilek, K.; Jun, D.; Kuca, K. New group of xylene linker-containing acetylcholinesterase reactivators as antidotes against the nerve agent cyclosarin. J. Enzyme Inhib. Med. Chem., 2006, 21, 515-9.
105. Kuca, K.; Cabal, J.; Jun, D.; Bajgar, J.; Hrabinova, M. Potency of new structurally different oximes to reactivate cyclosarin-inhibited human brain acetylcholinesterases. J. Enzyme Inhib. Med. Chem., 2006, 21, 663-6.
106. Racakova, V.; Hrabinova, M.; Jun, D.; Kuca, K. Substituted monoquaternary oximes as reactivators of cyclosarin - and chlorpyrifos - inhibited acetylcholinesterase. Arh. Hig. Rada Toksikol., 2006, 57, 387-90.
107. Bajgar, J.; Bartosova, L.; Fusek, J.; Jun, D.; Kuca, K. Equine butyrylcholinesterase protects rats against inhalation exposure to sublethal sarin concentrations. Arh. Hig. Rada. Toksikol., 2006, 57, 391-5.
108. Kuca, K.; Jun, D.; Bajgar, J. Currently used cholinesterase reactivators against nerve agent intoxication: comparison of their effectivity in vitro. Drug Chem. Toxicol., 2007, 30, 31-40.
109. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Opletalova, V.; Dolezal, M. Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker - synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett., 2007, 17, 3172-6.
110. Kuca, K.; Cabal, J.; Jun, D.; Musilek, K. In vitro reactivation potency of acetylcholinesterase reactivators - K074 and K075 - to reactivate tabun-inhibited human brain cholinesterases. Neurotox. Res., 2007, 11, 101-6.
111. Kuca, K.; Cabal, J.; Jun, D.; Hrabinova, M. Potency of five structurally different acetylcholinesterase reactivators to reactivate human brain cholinesterases inhibited by cyclosarin. Clin. Toxicol. (Phila)., 2007, 45, 512-5.
112. Kuca, K.; Jun, D.; Cabal, J.; Musilova, L. Bisquaternary oximes as reactivators of tabun-inhibited human brain cholinesterases: an in vitro study. Basic Clin. Pharmacol. Toxicol., 2007, 101, 25-8.
113. Kassa, J.; Jun, D.; Kuca K. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in cyclosarin-and tabun-poisoned rats. J. Enzyme Inhib. Med. Chem., 2007, 22, 297-300.
114. Musilek, K.; Holas, O.; Jun, D.; Dohnal, V.; Gunn-Moore, F.; Opletalova, V.; Dolezal, M.; Kuca, K. Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker: preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase. Bioorg. Med. Chem. 2007, 15, 6733-41.
115. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Dolezal, M. Synthesis of a novel series of non-symmetrical bispyridinium compounds bearing a xylene linker and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase. J. Enzyme Inhib. Med. Chem., 2007, 22, 425-32.
116. Kassa, J.; Jun, D.; Kuca, K.; Bajgar, J. Comparison of reactivating and therapeutic efficacy of two salts of the oxime HI-6 against tabun, soman and cyclosarin in rats. Basic. Clin. Pharmacol. Toxicol., 2007, 101, 328-32.
117. Kuca, K.; Musilek, K.; Paar, M.; Jun, D.; Stodulka, P.; Hrabinova, M.; Marek, J. Targeted synthesis of 1-(4-hydroxyiminomethylpyridinium)-3-pyridiniumpropane dibromide - a new nerve agent reactivator. Molecules, 2007, 12, 1964-72.
118. Kuca, K.; Jun, D.; Bajgar, J. Structural factors influencing potency of currently used acetylcholinesterase reactivators for treatment of cyclosarin intoxications. Curr. Pharm. Des., 2007, 13, 3445-52.
119. Kuca, K.; Jun, D. Reactivation of sarin-inhibited pig brain acetylcholinesterase using oxime antidotes. J. Med. Toxicol., 2006, 2, 141-6.
120. Jun, D.; Kuca, K.; Picha, J.; Koleckar, V.Marek, J. Potency of novel oximes to reactivate sarin inhibited human cholinesterases. Drug Chem. Toxicol., 2008, 31, 1-9.
121. Bajgar, J.; Kuca, K.; Jun, D.; Bartosova, L.; Fusek, J. Cholinesterase reactivators: the fate and effects in the organism poisoned with organophosphates/nerve agents. Curr. Drug Metab., 2007, 8, 803-9.
122. Musílek, K.; Kuca, K.; Jun, D. Evaluation of potency of known oximes (pralidoxime, trimedoxime, HI-6, methoxime, obidoxime) to in vitro reactivate acetylcholinesterase inhibited by pesticides (chlorpyrifos and methylchlorpyrifos) and nerve agent (Russian VX). Acta Med. (Hradec Kralove), 2007, 50, 203-6.
123. Musilek, K.; Holas, O.; Kuca, K.; Jun, D.; Dohnal, V.; Opletalova, V.; Dolezal, M. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J. Enzyme Inhib. Med. Chem., 2008, 23, 70-6.
124. Calić, M.; Bosak, A.; Kuca, K.; Kovarik, Z. Interactions of butane, but-2-ene or xylene-like linked bispyridinium para-aldoximes with native and tabun-inhibited human cholinesterases. Chem. Biol. Interact., 2008, 175, 305-8.
125. Berend, S.; Vrdoljak, A.L.; Radić, B.; Kuca, K. New bispyridinium oximes: In vitro and in vivo evaluation of their biological efficiency in soman and tabun poisoning. Chem. Biol. Interact., 2008, 175, 413-6.
126. Kassa, J.; Jun, D.; Karasova, J.; Bajgar, J.; Kuca, K. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in soman, cyclosarin and tabun-poisoned rats. Chem. Biol. Interact., 2008, 175, 425-7.
127. Bajgar, J.; Fusek, J.; Kassa, J.; Jun, D.; Kuca, K.; Hajek, P. An attempt to assess functionally minimal acetylcholinesterase activity necessary for survival of rats intoxicated with nerve agents. Chem. Biol. Interact. 2008, 175, 281-5.
128. Kassa, J.; Karasova, J.; Musilek, K.; Kuca, K.; Jung, Y.S. A comparison of the therapeutic and reactivating efficacy of newly developed oximes (K117, K127) and currently available oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Drug Chem. Toxicol., 2008, 31, 371-81.
129. Musilek, K.; Kucera, J.; Jun, D.; Dohnal, V.; Opletalova, V.; Kuca, K. Monoquaternary pyridinium salts with modified side chainsynthesis and evaluation on model of tabun- and paraoxoninhibited acetylcholinesterase. Bioorg. Med. Chem., 2008, 16, 8218-23.
130. Kassa, J.; Karasova, J.; Musilek, K.; Kuca, K.; Bajgar, J. An evaluation of reactivating and therapeutic efficacy of newly developed oximes (K206, K269) and commonly used oximes (obidoxime, HI-6) in cyclosarin-poisoned rats and mice. Clin. Toxicol. (Phila), 2008, 5, 1-5.
131. Kuca, K.; Cabal, J. In vitro reactivation of tabun-inhibited acetylcholinesterase using new oximes - K027, K005, K033 and K048. Cent. Eur. J. Public Health, 2004, 12(Suppl), S59-61.
132. Jun, D.; Kuca, K.; Cabal, J.; Bartosova, L.; Kunesova, G.; Kassa, J. Comparison of ability of some oximes to reactivate sarin-inhibited Monitoring the Pharmacokinetics of Pyridinium Aldoximes in the Body Mini-Reviews in Medicinal Chemistry, 2009, Vol. 9, No. 5 609 brain acetylcholinesterase from different species. Chem. Biol. Interact. 2005, 15, 385-7.
133. Jun, D.; Musilova, L.; Kuca, K.; Kassa, J.; Bajgar, J. Potency of several oximes to reactivate human acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon in vitro. Chem. Biol. Interact., 2008, 175, 421-424.
134. Pohanka, M.; Jun, D.; Kuca, K. In vitro reactivation of trichlorfon-inhibited butyrylcholinesterase using HI-6, obidoxime, pralidoxime and K048. J. Enzyme Inhib. Med. Chem., 2008, Sept 29, 1 [Epub ahead of print, PMID: 18825528].
135. da Silva, A.P.; Farina, M.; Franco, J.L.; Dafre, A.L.; Kassa, J.; Kuca, K. Temporal effects of newly developed oximes (K027, K048) on malathion-induced acetylcholinesterase inhibition and lipid peroxidation in mouse prefrontal cortex. Neurotoxicology, 2008, 29, 184-9.
136. Petroianu, G.A.; Nurulain, S.M.; Nagelkerke, N.; Shafiullah, M.; Kassa, J.; Kuca, K. Five oximes (K-27, K-48, obidoxime, HI-6 and trimedoxime) in comparison with pralidoxime: survival in rats exposed to methyl-paraoxon. J. Appl. Toxicol., 2007, 27, 453-7.
137. Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Sheen, R.; Kuca, K.; Petroianu, G.A. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol., 2007, 27, 482-90.
138. Kuca, K.; Pícha, J.; Jun, D. Reactivation potency of new group of acetylcholinesterase reactivators and their comparison with currently available oximes. Acta Med. (Hradec Kralove), 2006, 49, 233-5.
139. Kuca, K.; Patocka, J.; Cabal, J.; Jun, D. Reactivation of organophosphate-inhibited acetylcholinesterase by quaternary pyridinium aldoximes. Neurotox. Res., 2004, 6, 565-70.
140. Vojvodic, V.B.; Maksimovic, M. Absorption and excretion of pralidoxime in man after intramuscular injection of PAM-2CL and various cholinolytics. Eur. J. Clin. Pharmacol., 1972, 5, 58-61.
141. Jager, B.V.; Stagg, G.N.; Green, N.; Jager, L. Studies on distribution and disappearance of pyridine-2-aldoxime methiodide (PAM) and diacetyl monoxime (DAM) in man and in experimental animals. Bull. Johns Hopkins Hosp., 1958, 102, 225-34.
142. Holland, P.; Parkes, D.C. Plasma concentration of the oxime pralidoxime mesylate (P2S) after repeated oral and intramuscular administration. Br. J. Ind. Med., 1976, 33, 43-6.
143. Berglund, F.; Elwin, C.E.; Sundwall, A. Studies on the renal elimination of N-methylpyridinium-2-aldoxime. Biochem. Pharmacol., 1962, 11, 383-8.
144. Kondritzer, A.A.; Zvirblis, P.; Goodman, A.; Paplanus, S.H. Blood plasma levels and elimination of salts of 2-PAM in man after oral administration. J. Pharm. Sci., 1968, 57, 1142-6.
145. Uehara, S.; Hiromori, T.; Isobe, N.; Suzuki, T.; Kato, T.; Miyamato, J. Studies on the therapeutic effect of 2-pyridine aldoxime methiodide (2-PAM) in mammals following organophosphorous compound-poisoning (reprt III): distribution and antidotal effect of 2-PAM in rats. J. Toxicol. Sci., 1993, 18, 265-75.
146. Srivastava, A.K.; Malik, J.K. Intramuscular kinetics and dosage regiments for pralidoxime in buffalo calves (Bubalus bubalis). Vet. Res. Commun., 2001, 25, 301-9.
147. Holland, P.; Parkes, D.C.; White, R.G. Pralidoxime mesilate absorption and heart rate response to atripine sulphate following intramuscular administration of solution mixture. Br. J. Clin. Pharmacol., 1975, 2, 333-8.
148. Josselson, J.; Sidell, F.R. Effect of intravenous thiamine on pralidoxime kinetics. Clin. Pharm. Ther., 1978, 24, 95-100.
149. Sidell, F.R.; Groff, W.A. Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime metochloride to man. J. Pharm. Sci., 1971, 60, 1224-8.
150. Sidell, F.R.; Groff, W.A.; Kaminskis, A. Toxogonin and pralidoxime: kinetic comparison after intravenous administration to man. J. Pharm. Sci., 1972, 61, 1765-9.
151. Swartz, R.D.; Sidell, F.R. Renal tubular secretion of pralidoxime in man. Proc. Soc. Exp. Biol. Med., 1974, 146, 419-24.
152. Sidell, F.R.; Groff, W.A.; Ellin, R.I. Blood level of oxime and symptoms in human after a single and multiple oral doses of 2-pyridine aldoxime methochloride. J. Pharm. Sci., 1969, 58, 1093-8.
153. Sidell, F.R.; Groff, W.A.; Kaminskis, A. Pralidoxime methanesulfonate: plasma levels and and pharmacokinetics after oral administration to man. J. Pharm. Sci., 1972, 61, 1136-40.
154. Swartz, R.D.; Sidell, F.R. Effects of heat and exercise on the elimination of pralidoxime in man. Clin. Pharmacol. Ther., 1973, 14, 83-9.
155. Willems, J.L.; Langenberg, J.P.; Verstraete, A.G.; De Loose, M.; Vanhaesebroeck, B.; Goethals, B.; Belpaire, F.M.; Buylaert, W.A.; Vogelaers, D.; Colardyn, F. Plasma concentration of pralidoxime methylsulphate in organophosphorous patients. Arch. Toxicol., 1992, 66, 260-6.
156. Houzé, P.; Borron, S.W.; Scherninski, F.; Bousquet, B.; Gourmel, B.; Baud, F. Measurement of serum pralidoxime methylsulfate (Contrathion) by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B., 2005, 814, 149-54.
157. Medicis, J.J.; Stork, C.M.; Howland, M.A.; Hoffman, R.S.; Goldfrank, L.R. Pharmacokinetics following a loading plus continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. J. Toxicol. Clin. Toxicol., 1996, 34, 289-95.
158. Schexnayder, S.; James, L.P.; Kearns, G.L.; Farrar, H.C. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. J. Toxicol. Clin. Toxicol., 1998, 36, 549-55.
159. Thiermann, H.; Mast, U.; Klimmek, R.; Eyer, P.; Hibler, A.; Pfab, R.; Felgenhauer, N.; Zilker, T. Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. Hum. Exp. Toxicol., 1997, 16, 473-80.
160. Jovanovic, D.; Maksimovic, M.; Joksovic, V. Oral forms of the oxime HI-6: a study of pharmacokinetics and tolerance after administration to healthy volunteers. Vet. Hum. Toxicol., 1990, 32, 419-21.
161. Kusic, R.; Jovanovic, D.; Randjelovic, S.; Joksovic, D.; Todorovic, V,; Boskovic, B.; Jokanovic, M.; Vojvodic, V. HI-6 in man: efficacy of the oxime in poisoning by organophosphate insecticides. Hum. Exp. Toxicol., 1991, 10, 113-8.
162. Clement, J.C.; Bailey, D.G.; Madill, H.D.; Tran, L.T.; Spence, J.D. The acetylcholinesterase reactivator HI-6 in man: Pharmacokinetics and tolerability in combination with atropine. Biopharm. Drug Dist., 1995, 16, 415-25.
163. Busker, R.W.; Zijistra, J.J.; Philippens, I.H.C.H.M.; Groen, B.; Melchers, B.P.C. Comparison of the efficacz of single or repeated HI-6 treatment following soman poisoing in guinea pigs and marmost monkeys. Toxicology, 1996, 112, 183-94.
164. Lundy, P.M.; Hill, I.; Lecavalier, P.; Hamilton, M.G.; Vair, C.; Davidson, C.; Weatrbz, K.L.; Berger, B.J. The pharmacokinetics and pharmacodynamics of two HI-6 salts in swine and efficacy in the treatment of GF and soman poisoning. Toxicology, 2005, 208, 399-409.
165. Goransson-Nyberg, A.; Cassel, G.; Jeneskog, T.; Karlsson, L.; Larsson, R.; Lundstöm, M.; Palmer, L.; Persson, S.-A. Pharmacokinetics of HI-6 and atropine in anesthetized pigs after administration by a new autoinjector. Biopharm. Drug Dist., 1995, 16, 635-51.
166. Goransson-Nyberg, A.; Cassel, G.; Jeneskog, T.; Karlsson, L.; Larsson, R.; Lundstöm, M.; Persson, S.-A. Treatment of organophosphate poisoning in pigs antidote administration by a new binary autoinjector. Arch. Toxicol., 1995, 70, 20-7.
167. De La Motte, S.; Szinicz, L. pyridinium, 1[(4-carbamoyl-pyridino) methoxy]methyl-2-(hydroxyimino-methyl) dichloride monohydrate (HI-6) and atropine on the circulation and respiration of anesthetized guinea pigs. In: Recent Developments in Toxicology: Trends Methods and Problems. Arch. Toxicol., 1991, (Suppl.) 14, 66-8.
168. Klimmek, R.; Eyer, P. Pharmacokinetics and pharmcodynamics of the oxime HI-6 in dogs. Arch. Toxicol., 1986, 59, 272-8.
169. Spohrer, U.; Thiermann, H.; Klimmek, R.; Eyer, P. Pharmacokinetics of the oximes HI-6 and Hio7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. Arch. Toxicol., 1994, 68, 480-9.
170. Okuno, S.; Sakurada, K.; Ohta, H.; Ikegaya, H.; Kazui, Y.; Akutso, T.; Takatori, T.; Iwadate, K. Blood-brain barrier penetration of novel pyridine aldoxime methiodide (PAM)-type oximes examined by brain microdialysis with LC-MS/MS. Toxic. Appl. Pharmacol., 2008, 227, 8-15.
171. Sakurada, K.; Matsubara, K.; Shimizu, K.; Shiono, H.; Seto, Y.; Tsuge, K.; Yoshino, M.; Sakai, I.; Mukoyama, H.; Takatori, T. 610 Mini-Reviews in Medicinal Chemistry, 2009, Vol. 9, No. 5 Kalász et al. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem. Res., 2003, 28, 1401-1407.
172. Milosevic, M.P.; Andjelkovic, D. Reactivation of paraoxonin-activated cholinesterase in the rat cerebral cortex by pralidoxime chloride. Nature, 1966, 210, 206.
173. Clement, J.G. Efficacy of various oximes against GF (cyclohexyl methylphosphonofluoridate) poisoning in mice. Arch. Toxicol., 1992, 66, 143-4.
174. Garrigue, H.; Maurizis, J.C.; Nicolas, C.; Madelmont, J.C.; Godeneche, D.; Hulot, T.; Morge, X.; Demerseman, P.; Sentenac-Roumanou, H.; Veyre, A. Disposition and metabolism of two acetylcholinesterase reactivators, pyrimidoxime and HI-6, in rats submitted to organophosphate poisoning. Xenobiotica, 1990, 20, 699-709.
175. Tekes, K.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludányi, K.; Kalász, H. High-performance liquid chromatographic determination of the plasma concentration of K-27, a novel oxime-type cholinesterase reactivator. J. Chromatogr. A., 2006, 1122, 84-7.
176. Gyenge, M.; Kalász, H.; Petroianu, G.A.; Laufer, R.; Kuca, K.; Tekes, K. Measurement of K-27, an oxime-type cholinesterase reactivator by high-performance liquid chromatography with electrochemical detection from different biological samples. J. Chromatogr. A., 2007, 1161, 146-51.
177. Kalász, H.; Hasan, M.Y.; Sheen, R.; Kuca, K.; Petroianu, G.; Ludányi, K.; Gergely, A.; Tekes, K. HPLC analysis of K-48 concentration in plasma. Anal. Bioanal. Chem., 2006, 385, 1062-7.
178. Robert, D.M.; Buckley, N.A. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin. Pharmacokinet., 2007, 46, 897-939.
179. Rubnov, S.; Shats, I.; Levy, D.; Amisar, S.; Schneider, H. Autocatalitic degradation and stability of obidoxime. J. Pharm. Pharmacol., 1999, 51, 9-14.
180. Csermely, T.; Kalász, H.; Petroianu, G.; Kuca, K.; Darvas, F.; Ludányi, K.; Mudhafar, A.A.; Tekes, K. Analysis of pyridinium aldoximes - A chromatographic approach. Curr. Med. Chem., 2008, 15, 2401-18.
181. Houzé, P.; Thabet, H.; Delfour, A.; Larrouy, L.; Le Bricon, T.; Baud, F.J. Quantification of pralidoxime methylsulfate (Contrathion) in human urine by capillary zone electrophoresis. J. Chromatogr. B., 2005, 826, 63-8.
182. Kalász, H.; Szöko, É.; Tábi, T.; Petroianu, G.; Loorke, D.E.; Alafifi, O.A.; Almern, S.J.; Tekes, K. Analysis of pralidoxime in serum, brain and CSF of rats. Med. Chem.,acceped for publication.
183. Way, J.L.; Way, E.L. The metabolism of alkylphosphate antagonists and its pharmacologic implications. Ann. Rev. Pharmacol., 1968, 8, 187-212.
184. Gibbon, S.L.; Way, J.L. Rapid method for investigating the in vivo metabolism of 1-methyl-2-aldoximinopyridinium iodide by ion exchange column chromatography. J. Chromatogr., 1967, 26, 202-7.
185. Ligtenstein, D.A.; Wils, E.R.; Kossen, S.P.; Hulst, A.G. Identification of two metabolites of the cholinesterase reactivator HI-6 isolated from rat urine. J. Pharm. Pharmacol., 1987, 39, 17-23.
186. Morgan, R.L.; Burrows, G.E.; Yen, M.H.; Way, J.L. Metabolic disposition of the alkylphosphate antagonist, 1,1'-trimethylenebis-1- (4-aldoximinopyridinium)-1'- (4-carboxamidopyridinium) ion. Drug Metab. Dist., 1982, 10, 491-4.
187. Benko, B.; Laufer, R.; Ohmacht, R. HPLC analysis of microsomal metabolism of K-48. Acta Chromatogr., 2007, 19, 61-72.
188. Benkć, B.; Kalász, H.; Ludányi, K.; Petroianu, G.; Kuca, K.; Darvas, F.; Tekes, K. In vitro and in vivo metabolism of K-48. Anal. Bioanal. Chem., 2007, 389, 1243-7.
189. Zhang, Z.; Lockman, P.R.; Mittapalli, R.K.; Allen, D.D.; Dwoskin, L.P.; Crooks, P.A. Bis-pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter. Bioorg Med, Chem. Lett., 2008, 18, 5622-5.
190. Davson, H.; Segal, M. Physiology of the CSF and Blood-Brain-Barriers, CRC Press, Boca Raton, Fl., 1996.
191. Pardridge, W.M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 2002, 1, 131-9.
192. Lorke, D.; Kalász, H.; Petroianu, G.; Tekes, K. Entry of oximes into the brain: a review. Curr. Med. Chem., 2008, 15, 743-53
193. Shimizu, K.; Ohtaki, K.; Matsubara, K.; Aoyama, K.; Uezono, T.; Saito, O.; Suno, M.; Ogawa, K.; Hayase, N.; Kimura, K.; Shiono, H. Carrier-mediated processes in blood-brain penetration and neural uptake of paraquat. Brain Res., 2001, 906, 135-142.
194. Geldenhuys, W.J.; Lockman, P.R.; McAfee, J.H.; Fitypatrick, K.T.; Van der Schzf, C.J.; Allen, D.D. Molecular modeling studies on the active binding site of blood/brain barrier choline transporter. Bioorg. Med. Chem., 2004, 14, 3085-92.
195. Firemark, H.; Barlow, C.F.; Roth, L.J. The penetration of 2-PAMC-14 into brain and the effect of cholinesterase inhibitors on transport. J. Pharmacol. Exp. Ther., 1964, 145, 252-65.
196. Lorke, D.E.; Hasan, M.Y.; Nurulain, S.M.; Sheen, R.; Kuca, K.; Petroianu, G.A. Entry of two new asymmetric bis-pyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol., 2007, 27, 482-90.
197. Bodor, N.; Roller, R.G.; Selk, S.J. Elimination of quaternary pyridinium salts delivered as its dihydropyridine derivative from brain of mice. J. Pharm. Sci., 1978, 67, 685-7.
198. Bodor, N.; Shek, E.; Higuchi, T. Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science, 1975, 190, 155-6.
199. Shek, E.; Higuchi, T.; Bodor, N. Improved delivery through biological membranes. 3. Delivery of N-methylpyridinium-2-carbaldoxime chloride through the blood-brain barrier in its dihydropyridine pro-drug form. J. Med. Chem., 1976, 9, 113-7
200. Petroianu, G.A.; Lorke, D.E.; Hasan, M.; Adem, A.; Sheen, R.; Nurulain, S.M.; Kalász, H. Paraoxon has only a minimal effect on pralidoxime brain concentration in rats. J. Appl. Toxicol., 2007, 27, 350-7.
201. Lorke, D.E.; Kalász, H.; Petroianu, G.A.; Tekes, K. Entry of oximes into the brain: a review. Curr. Med. Chem., 2008, 15, 743-53.
202. Ballantyne, B.; Swanston, D.W. Aqueous humour pralidoxime mesylate (P2S) concentration and intraocular tension following intramuscular P2S. Drug. Chem. Toxicol., 1980, 3, 259-75.
203. Petroianu, G.A.; Missler, A.; Zuleger, K.; Thyes, C.; Ewald, V.; Maleck, W.H. Enzyme reactivator treatment in organophosphate exposure: clinical relevance of thiocholinesteratic activity of pralidoxime. J. Appl. Toxicol., 2004, 24, 429-35.
204. Peter, J.V.; Moran, J.L.; Pichamutu, K.; Chacko, B. Adjuncts and alternatives to oxime therapy in organophosphate poisoning - is there evidence of benefit in human poisoning? A review. Anaesth. Intensive Care, 2008, 36, 339-50.
205. Kalász, H.; Tekes, K. Terrorist attacks or poisoning by organophosphate pesticides - is there any defence? BenSci., accepted for publication, 2008.